Vista Pharmaceuticals Ltd Fair Value
VISTAPH · Healthcare · Current price ₹7.15
| Method | Fair value | Status |
|---|---|---|
| Residual income | ₹4 | -10% ROE fading to 12% over ~3 yrs, on ₹6 book |
| Relative P/E | — | Needs positive EPS |
| Graham floor | — | Needs positive EPS |
| Analyst target | — | No analyst coverage |
Is Vista Pharmaceuticals Ltd undervalued?
DocStoX estimates the fair value of Vista Pharmaceuticals Ltd at ₹4 per share, versus the current market price of ₹7. That puts the stock about -44.1% above our fair-value estimate, which we read as "Avoid". Our confidence in this estimate is low.
How this fair value is calculated
This estimate blends 1 independent method: Residual income (₹4). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹3 (bear) to ₹4 (base) to ₹5 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
More on Vista Pharmaceuticals Ltd
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.